Information on this page is intended for Ireland healthcare professionals only and may contain promotional material
Tillotts in Ireland
Tillotts Pharma Ltd Ireland is proud to be based in Dublin and part of the the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, part of the Japanese Zeria Group.
GI health is our passion at Tillotts
With over 30 years’ expertise in developing and manufacturing treatments for inflammatory bowel disease (IBD), we understand the disease, the market and the challenges GI healthcare professionals and patients face.
Tillotts Pharma Ireland is an expert in GI health products and provides support in the following areas:
- Inflammatory Bowel Disease
- Clostridioides difficile Infections
Enhancing patient care
Tillotts Pharma Ireland strives to be the preferred partner in GI health and are committed to supporting healthcare professionals to improve outcomes for patients. Tillotts is motivated by the aim to consistently deliver quality and value to healthcare professionals and are dedicated to improving the lives of people with GI disease and supporting those who care for them.
Supporting healthcare professionals
We’re committed to supporting our healthcare colleagues where possible, which is why we support external congresses and events that provide valuable learning opportunities for Ireland healthcare professionals and sponsor individual attendance where appropriate.
An award-winning organisation
Tillotts Pharma has received several industry-recognised awards, most recently the 2025 Communiqué Award for “Excellence in national or local education meetings/stand-alone events”.
TPUK has also recieved Gold and Silver PM Society Awards in 2018 and a Gold Communiqué Award in 2019 and were awarded the first Tillotts Star award. This award recognized the growth and development of Tillotts UK, which is now Tillotts largest affiliate.
Seeking partnerships
Tillotts actively seeks partnership and in-licensing opportunities to add to our portfolio of medicines. We are particularly interested in products that may be off-patent or are currently not being actively promoted, where we can breathe life back into the brand, help fulfil any unmet patient needs, and provide value to the healthcare professionals.
Case studies and testimonials are available on request for interested parties.
NP-TP-IE-00018 | March 2026
The information on the following pages is only intended for patients within Ireland who have been prescribed Asacolon, Dificlir or Entocort CR 3 mg Capsules
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie/report-an-issue/medicines-for-human-use/side-effects.
Adverse events should also be reported to Tillotts Pharma UK and Ireland on +353 1 2942015 or pvireland@tillotts.com
You are about to leave tillotts.ie for an external website. Tillotts is not responsible for the content of other websites.